Exponent, Inc. (EXPO) Company Overview

Exponent, Inc. is an engineering and scientific consulting firm listed on the Nasdaq Global Select Market under ticker EXPO. It is hired when a client needs defensible technical judgment: determining why a product failed, testing whether a design is safe, evaluating environmental or health effects, supporting a regulatory submission, or explaining complex evidence in a dispute. The firm describes its work across more than 90 technical disciplines and 17 practices, a breadth that lets it assemble multidisciplinary teams around unusually difficult problems. Its official company overview connects the modern business to its original role in root-cause investigations.

Which services and customers define the firm?

Customers include corporations, startups, law firms, insurers and governments. Work uses offices, laboratories and computing resources across North America, Europe and Asia. No individual client represented more than 10% of revenue in the first quarter of fiscal 2026, reducing dependence on a single account even though demand can still cluster around industries such as consumer electronics, energy, construction, transportation, medical devices and chemicals.

Exponent sells expert time, access to specialized facilities and the credibility of independent analysis. Consultants record billable hours, the firm charges negotiated rates, and clients reimburse certain travel, testing and project costs. Management therefore emphasizes revenue before reimbursements, also called net revenue, because reimbursements carry little or no margin and can make headline revenue growth look stronger than underlying consulting activity.

Which segment drives revenue and profit?

The newest available reporting period is the first quarter of fiscal 2026, ended April 3, 2026. Exponent's official earnings release showed strong consulting demand, while the Q1 FY2026 Form 10-Q provides the underlying expense, cash-flow and segment detail.

Was growth broad-based or concentrated?

Total revenue reached $166.3 million, with reimbursement growth making the 10.5% increase in net revenue the cleaner operating signal. Demand included AI-related consumer-device research, utility risk management, energy and construction disputes, and life-sciences and medical-device assignments. Environmental and Health growth came mainly from chemical-industry regulatory consulting.

Engineering produced stronger hours, staffing and segment profit. Environmental and Health utilization fell to 69%, showing a healthy consolidated quarter but clear divergence between the segments.

Exponent's history matters because it explains both the firm's reputation and its current growth strategy. It began with reactive work—finding the root cause after something went wrong—but gradually added proactive product, health, environmental and regulatory capabilities. The official history shows how expansion preserved the original investigative culture while broadening the addressable market.

1. 1967
   Three Stanford professors and two Stanford Research Institute engineers founded Failure Analysis Associates, establishing root-cause investigation as the firm's foundational capability.
2. 1990
   The company went public on Nasdaq under ticker FAIL, giving it permanent capital and a public-market framework for expanding specialist talent and facilities.
3. 1991
   European expansion began, supporting multinational clients and creating the early base for today's cross-border service model.
4. 1996–1997
   Environmental Health Strategies and PTI Environmental Services were acquired, turning health and environmental science into a second reportable economic pillar.
5. 1998
   The name changed to Exponent, signaling a broader identity than post-failure engineering alone.
6. 2002
   A first China office and the acquisition of Novigen Sciences expanded geographic reach and strengthened chemical regulation and food-safety expertise.
7. 2018
   Catherine Corrigan became CEO, continuing an internally developed leadership model and emphasizing talent, scientific excellence and cross-disciplinary collaboration.

What strategic tension still defines the company?

Exponent does not have a conventional network effect or a patent-protected product. Its advantage is a compound intangible asset: specialist talent, accumulated case knowledge, physical testing capability, independence and a reputation that matters when conclusions may be challenged by regulators, courts, insurers or opposing experts. The 2025 filing describes the market as fragmented with relatively low formal barriers to entry, so the moat is earned repeatedly through execution rather than protected by regulation.

Who competes with Exponent?

Competition comes from several directions rather than one exact peer. Specialist engineering boutiques can be highly credible within a narrow domain. Economic and litigation consultancies compete for dispute-related budgets. Multidisciplinary engineering firms can bundle analysis with design or project delivery. Clients can also use internal engineers and scientists, although an external expert may be preferred when independence is important.

The most useful operating model is straightforward: technical full-time equivalents multiplied by available hours, utilization and realized billing rates produces net revenue. Compensation and occupancy then determine how much of that revenue becomes profit. Because clients can terminate projects and management says backlog is not a meaningful indicator, researchers should prioritize live utilization, billable hours, hiring and rate realization over contracted-order metrics.

Why is backlog less useful here?

Exponent combines high margins with modest capital requirements, although cash flow is seasonal. FY2025 revenue was $582.0 million, operating income was $119.8 million and net income was $106.0 million. Operating cash flow of $131.7 million less $9.1 million of capital expenditures produced about $122.7 million of calculated free cash flow.

What changed between the annual baseline and Q1?

How does management allocate cash?

The April 3, 2026 balance sheet did not separately report funded borrowings, but it included lease obligations and deferred-compensation liabilities matched by designated assets. The main allocation question is whether buybacks, dividends and hiring preserve enough flexibility for technology, laboratories and cyclical demand. Exponent's financial-information hub provides the official updates.

Exponent has one class of common stock with one vote per share and no cumulative voting. That makes it a conventionally governed public company rather than a founder-controlled or dual-class structure. The latest 2026 proxy statement reported 48,614,692 shares outstanding on the April 8, 2026 record date and showed a shareholder base led by large institutions.

What does the 2026 leadership transition signal?

The leadership transition announcement preserved continuity: the new president and CFO are long-tenured insiders, Corrigan remains CEO, and Rich Schlenker remains executive vice president. The leadership page reinforces internal development, which protects culture but raises the importance of succession depth.

Complex technology, infrastructure and regulation create demand for specialized evidence and independent judgment. Q1 FY2026 work included AI-related consumer-device research, utility risk management, energy and construction disputes, life sciences and chemical regulation. The same forces can also pressure pricing, delivery and liability.

Which risks could weaken the model?

A discounted cash-flow model should begin with net revenue because reimbursements carry different economics. The core variables are technical headcount, utilization, billable hours, billing rates and compensation inflation. Modest capital spending supports cash conversion, but quarterly cash flow should be normalized for bonus timing and working capital.

Which assumptions matter most in a DCF?

What should a student, researcher or investor watch next?

• Whether net-revenue growth remains in management's high-single-digit FY2026 range.
• Whether consolidated utilization stays near or above the Q1 FY2026 level while technical headcount expands.
• The gap between billing-rate growth and compensation inflation.
• Engineering's continued strength versus Environmental and Health's weaker hours and utilization.
• EBITDA margin relative to the FY2026 guidance range of 27.6%–28.1%.
• Free cash flow after seasonal bonus payments, working-capital changes, dividends and repurchases.
• Whether AI creates premium demand faster than it commoditizes work.
• Execution by the new leadership configuration and independent board chair.